Prestige Brands Navigates Converting M&A Into Organic Growth
This article was originally published in The Tan Sheet
Prestige Brands reports 2.6% growth in latest quarter to $165.1m in US sales of OTC drugs including BC and Goody's analgesic brands and Ludens and Chloraseptic throat lozenge brands, but international sales, a focus area for growth, dropped 11.2% to $13.8m due to currency exchange rates.
You may also be interested in...
Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.
Approvals by FDA also include revised container and consumer information labeling for J&J's Men’s Rogaine to align with labeling for Women’s Rogaine; bonus-pack labeling for Bayer AG’s Aleve; and
During JP Morgan conference, Alex Gorsky suggests responding to pandemic is changing health care, including businesses providing pharmaceuticals, medical technologies, nutritionals and other necessary products.